124 related articles for article (PubMed ID: 6409188)
1. Use of an antibody-ricin A-chain conjugate to delete neoplastic B cells from human bone marrow.
Muirhead M; Martin PJ; Torok-Storb B; Uhr JW; Vitetta ES
Blood; 1983 Aug; 62(2):327-32. PubMed ID: 6409188
[TBL] [Abstract][Full Text] [Related]
2. Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish in vitro hematopoiesis in long-term marrow cultures.
La Russa VF; Griffin JD; Kessler SW; Cutting MA; Knight RD; Blattler WA; Lambert JM; Wright DG
Exp Hematol; 1992 May; 20(4):442-8. PubMed ID: 1373688
[TBL] [Abstract][Full Text] [Related]
3. Autologous transplantation of bone marrow purged in vitro with anti-CD7-(WT1-) ricin A immunotoxin in T-cell lymphoblastic leukemia and lymphoma.
Preijers FW; De Witte T; Wessels JM; De Gast GC; Van Leeuwen E; Capel PJ; Haanen C
Blood; 1989 Aug; 74(3):1152-8. PubMed ID: 2473811
[TBL] [Abstract][Full Text] [Related]
4. Elimination of clonogenic tumor cells from human bone marrow using a combination of monoclonal antibody:ricin A chain conjugates.
Bregni M; De Fabritiis P; Raso V; Greenberger J; Lipton J; Nadler L; Rothstein L; Ritz J; Bast RC
Cancer Res; 1986 Mar; 46(3):1208-13. PubMed ID: 3510720
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of monoclonal antibody DF3 conjugated with ricin as a specific immunotoxin for in vitro purging of human bone marrow.
Tondini C; Pap SA; Hayes DF; Elias AD; Kufe DW
Cancer Res; 1990 Feb; 50(4):1170-5. PubMed ID: 2404589
[TBL] [Abstract][Full Text] [Related]
6. Selective killing of normal or neoplastic B cells by antibodies coupled to the A chain of ricin.
Krolick KA; Villemez C; Isakson P; Uhr JW; Vitetta ES
Proc Natl Acad Sci U S A; 1980 Sep; 77(9):5419-23. PubMed ID: 6968912
[TBL] [Abstract][Full Text] [Related]
7. Preclinical studies on the use of selective antibody-ricin conjugates in autologous bone marrow transplantation.
Leonard JE; Taetle R; To D; Rhyner K
Blood; 1985 May; 65(5):1149-57. PubMed ID: 3888307
[TBL] [Abstract][Full Text] [Related]
8. Protein A vectorized toxins--II. Preparation and "in vitro" cytotoxic effect of protein A-ricin A chain conjugate on antibody coated human tumour cells.
Ghetie MA; Moraru I; Margineanu M; Ghetie V
Mol Immunol; 1988 May; 25(5):473-7. PubMed ID: 3412331
[TBL] [Abstract][Full Text] [Related]
9. Immunotoxin-mediated elimination of clonogenic tumor cells in the presence of human bone marrow.
Uckun FM; Ramakrishnan S; Houston LL
J Immunol; 1985 Mar; 134(3):2010-6. PubMed ID: 3855433
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma.
Grossbard ML; Gribben JG; Freedman AS; Lambert JM; Kinsella J; Rabinowe SN; Eliseo L; Taylor JA; Blättler WA; Epstein CL
Blood; 1993 May; 81(9):2263-71. PubMed ID: 8481509
[TBL] [Abstract][Full Text] [Related]
11. High frequency of lambda gene activation in bone marrow pre-B cells.
Nishikawa SI; Kina T; Gyotoku JI; Katsura Y
J Exp Med; 1984 Feb; 159(2):617-22. PubMed ID: 6420503
[TBL] [Abstract][Full Text] [Related]
12. An immunotoxin with therapeutic potential in T cell leukemia: WT1-ricin A.
Myers CD; Thorpe PE; Ross WC; Cumber AJ; Katz FE; Tax W; Greaves MF
Blood; 1984 May; 63(5):1178-85. PubMed ID: 6370334
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the systemic toxicity and pharmacokinetics of the immunoconjugate anti-B4-blocked ricin in non-human primates. Delivered by multiple bolus injections and by continuous infusion.
Shah SA; Lambert JM; Goldmacher VS; Esber HJ; Levin JL; Chungi V; Zutshi A; Braman GM; Ariniello PD; Taylor JA
Int J Immunopharmacol; 1993 Aug; 15(6):723-36. PubMed ID: 7691767
[TBL] [Abstract][Full Text] [Related]
14. Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells.
Roy DC; Griffin JD; Belvin M; Blättler WA; Lambert JM; Ritz J
Blood; 1991 Jun; 77(11):2404-12. PubMed ID: 2039821
[TBL] [Abstract][Full Text] [Related]
15. Specific ex-vivo depletion of human bone marrow T lymphocytes by an anti-pan-T cell (CD5) ricin A-chain immunotoxin.
Siena S; Villa S; Bonadonna G; Bregni M; Gianni AM
Transplantation; 1987 Mar; 43(3):421-6. PubMed ID: 3103275
[TBL] [Abstract][Full Text] [Related]
16. Optimal elimination of leukemic T cells from human bone marrow with T101-ricin A-chain immunotoxin.
Casellas P; Canat X; Fauser AA; Gros O; Laurent G; Poncelet P; Jansen FK
Blood; 1985 Feb; 65(2):289-97. PubMed ID: 3871341
[TBL] [Abstract][Full Text] [Related]
17. Evidence for absence of toxicity of T101 immunotoxin on human hematopoietic progenitor cells prior to bone marrow transplantation.
Douay L; Gorin NC; Lopez M; Casellas P; Liance MC; Jansen FK; Voisin GA; Baillou C; Laporte JP; Najman A
Cancer Res; 1985 Jan; 45(1):438-41. PubMed ID: 3880666
[TBL] [Abstract][Full Text] [Related]
18. Synergy between immunotoxins prepared with native ricin A chains and chemically-modified ricin B chains.
Vitetta ES
J Immunol; 1986 Mar; 136(5):1880-7. PubMed ID: 2419417
[TBL] [Abstract][Full Text] [Related]
19. [Selective cytotoxicity of antibody-ricin-A-chain conjugate for human tumor B cells. II. Comparison of activity of immunotoxins conjugated with poly- and monoclonal antibodies].
Tonevitskiĭ AG; Zhukova OS; Rakhmanova VA; Arsen'eva EL; Bogacheva GT
Mol Biol (Mosk); 1988; 22(4):911-6. PubMed ID: 3141780
[TBL] [Abstract][Full Text] [Related]
20. The effect of antibody valency and lysosomotropic amines on the synergy between ricin A chain- and ricin B chain-containing immunotoxins.
Fulton RJ; Uhr JW; Vitetta ES
J Immunol; 1986 Apr; 136(8):3103-9. PubMed ID: 3958490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
